Document:

<PAGE>

                                                                    Exhibit 10.5

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                           Exclusive License Agreement
                           ---------------------------

         This is an agreement between

         Siemens Medical Systems, Inc. ("Licensor")
         186 Wood Avenue South
         Iselin NJ 08830

a Delaware corporation, acting through Wolfgang Kroll, its Executive
Vice-President, and

         LipoMed, Inc. ("Licensee")
         1117 Wellstone Circle
         Apex NC 27502

a North Carolina corporation, acting through Michael A. Harpold, its President,

         WHEREAS Licensor owns U.S. Patent No. 4,933,844 (the "'844 patent") and
foreign counterpart applications thereto as listed on Schedule A; and

         WHEREAS Licensee wishes to obtain an exclusive license, under the `844
patent and its counterpart applications, in order to sell certain blood testing
services and Licensor is willing to grant such license;

         NOW THEREFORE, in consideration of their mutual promises, and intending
to be legally bound, the parties hereto agree as follows:

         1.       License Grant   Licensor hereby grants to Licensee, and
                  -------------
Licensee hereby accepts, an exclusive license to U.S. Patent No. 4,933,844 and
counterpart patents and patent application thereto as listed on Schedule A. The
'844 patent, and all the patents and patent applications listed on Schedule A,
are hereinafter referred to collectively as "Patent Rights".

                  1.1   Territory The license herein granted covers a territory
                        ---------
                  (hereinafter, the "Territory") that is coextensive with all
                  territories covered by the Patent Rights.

                  1.1.1 Territorial Changes If the parties mutually agree that
                        -------------------
                  one or more of the patents in Schedule A may be permitted to
                  lapse, the territory defined at paragraph 1.1 above will be
                  automatically amended to remain

<PAGE>

                  coextensive with the territory covered by the remaining
                  effective Patent Rights.

                  1.2      Term The license herein granted will commence on the
                           ----
                           Effective Date of this agreement, and will terminate
                           upon the expiration of the last-to-expire one of the
                           Patent Rights, unless sooner terminated in accordance
                           with the terms hereof.

                  1.3      Scope  The license herein granted includes:
                           -----
                           a)  The exclusive right to practice the invention
                               claimed in the Patent Rights;
                           b)  The exclusive right to grant sublicenses to
                               others to practice the invention claimed in the
                               Patent Rights; and
                           c)  The exclusive right to enforce the Patent Rights
                               against others.

         2.       Compensation to Licensor  As compensation for the license
                  ------------------------
herein granted to Licensee, Licensee agrees to make the following payments to
Licensor:

                  2.1      Lump Sum Reimbursement Licensee will pay Licensor the
                           ----------------------
                  sum of $[**]. This sum will become due and payable [**] months
                  after the Effective Date of this agreement. The parties agree
                  that this sum represents a) the unpaid portion of a debt owed
                  by James D. Otvos to Siemens AG, plus b) certain other costs
                  incurred by Licensor in connection with the granting of this
                  license.

                  2.2      Patent Maintenance Fees Licensee will reimburse
                           -----------------------
                  Licensor for all out-of-pocket costs to maintain the Patent
                  Rights in force during the term defined in paragraph 1.2
                  above. Such costs include, but are not limited to: maintenance
                  fees, requests for examination, and fees to local patent
                  attorneys not employed full-time by Licensor or Siemens
                  companies. Licensee will reimburse Licensor for all such costs
                  within 30 days after Licensor invoices Licensee for such
                  costs; Licensee is entitled to copies of such documentation as
                  is reasonably required to establish that such costs are
                  properly payable.

                  2.3      Minimum Annual Running Royalty Licensee will pay
                           ------------------------------
                  Licensor a minimum annual running royalty of $[**]. If by
                  December 31 in any calendar year Licensee has not accrued
                  running royalties payable to Licensor of at least $[**] during
                  that calendar year, Licensee will increase such accrued
                  running royalties payable to $[**] and will pay such amount to
                  Licensor in Licensee's January payment.

                  2.3.1    Investigative Phase Exception No minimum annual
                           -----------------------------
                  running royalties will be payable during the Investigative
                  Phase of this license. As used herein, "Investigative Phase"
                  means a period of time that

                                        2

<PAGE>

                           a)   Commences on the Effective Date of this
                                agreement, and
                           b)   Ends 24 months after Licensee has received all
                                approvals necessary to sell its blood-testing
                                services in interstate commerce.

                  2.4      Running Royalties  Licensee will pay Licensor running
                           -----------------
                  royalties based on Licensee's Net Sales of blood tests that
                  are

                           a)   carried out in the Territory; and/or
                           b)   carried out at the request of Licensee customers
                                that are located in the Territory.

                  2.4.1    Royalty Rate Schedule The royalty rate applicable to
                           ---------------------
                  Licensee's Net Sales depends as follows upon the cumulative
                  Net Sales made by Licensee from the Effective Date of this
                  agreement until the current Computation Date (defined below at
                  paragraph 2.4.2):

                           a)   For cumulative Net Sales from $[**] to
                                $[**]--[**]%;
                           b)   For cumulative Net Sales from $[**] to
                                $[**]--[**]%;
                           c)   For cumulative Net Sales above $[**]: --[**]%

                  2.4.2    Running Royalty Computations and Accruals Licensee
                           -----------------------------------------
                  will compute, and will accrue on its books, running royalties
                  due to Licensor as of four Computation Dates each year, namely
                  March 31, June 30, September 30, and December 31. In each such
                  computation, Licensee's Net Sales between the prior
                  Computation Date and the current Computation Date will be
                  multiplied by the applicable running royalty rate to compute
                  the running royalties due to Licensor.

                  2.4.3    Payment of Running Royalties Licensee will pay
                           ----------------------------
                  Licensor all accrued running royalties due to Licensor within
                  [**] days after each Computation Date, i.e. by [**], and [**].

                  2.4.4    Net Sales The parties agree that "Net Sales", as used
                           ---------
                  herein, means the gross invoiced amount of all sales made by
                  Licensee, less:

                           a)   Returns, allowances, discounts and rebates;
                           b)   Sales taxes and any other sums required by law
                                to be charged to Licensee's customers and
                                remitted to any governmental agency; and
                           c)   Licensee's out-of-pocket costs for
                                transportation and handling of blood samples.

                  2.4.4.1  Arm's Length Principles Licensee agrees that if it
                           -----------------------
                  makes any sales or purchases other than on an "arms-length"
                  basis, the fair market value of

                                        3

<PAGE>

                  such sales or purchases will be used for purposes of paragraph
                  2.4.4 above.

                  2.4.5 Late Payments Licensee agrees to pay interest at the
                        -------------
                  annual rate of [**]% on each payment not paid by the date on
                  which it is due. The interest will accrue from the due date
                  until the date on which payment is actually made.

                  2.5   Sublicenses If Licensee grants sublicense rights to any
                        -----------
                  third party, Licensee will pay running royalties to Licensor
                  based upon Net Sales made by the third party.

                  2.5.1 Amount of Running Royalties The parties agree that all
                        ---------------------------
                  sales made by a sublicensee will be deemed to have been made
                  by Licensee. Licensee agrees to pay running royalties on such
                  third party sales as if it had made such sales on its own. The
                  parties agree that the actual consideration for any sublicense
                  rights, as between Licensee and any third party, is irrelevant
                  to the royalty payment obligation owed by Licensee to
                  Licensor.

                  2.5.2 Licensee Responsible for Sales by Its Sublicensees The
                        --------------------------------------------------
                  parties agree that Licensee is responsible for paying running
                  royalties to Licensor on all sales made by its sublicensees.
                  The parties agree that a default by any sublicensee on any
                  obligation owed to Licensee shall not affect Licensee's
                  obligations hereunder to Licensor.

                  2.5.3 Exclusive Sublicenses to Require Licensor's Consent The
                        ---------------------------------------------------
                  parties agree that Licensee may not, without Licensor's
                  written consent, grant any exclusive sublicense to the Patent
                  Rights, or to any part thereof.

                  2.5.4 Sublicenses to Be Available for Licensor's Inspection
                        -----------------------------------------------------
                  and Audit If Licensee grants any sublicense rights to the
                  ---------
                  Patent Rights, or to any part thereof, Licensee agrees to make
                  all sublicense documents available to Licensor for its
                  inspection and (if necessary) audit.

                  2.5.5 Sublicenses Agreements to Require Marking Licensee
                        ----------------------
                  agrees that if it grants sublicense rights to the Patent
                  Rights or any part thereof, each sublicensee will be obliged
                  to use the legend set forth at paragraph 6 below. The parties
                  agree that this is a material term of this agreement and that
                  breach thereof by any sublicensee will, if not cured in
                  accordance with the provisions hereof, entitle Licensor to
                  terminate this agreement.

                  2.6   Payments Licensee will make all payments provided for
                        --------
                  herein in U.S. dollars, and in immediately available funds.

                                        4

<PAGE>

         3.       Royalty Reports and Records Licensee will maintain accounting
                  ---------------------------
records that accurately record its sales and will retain such records for at
least [**] after the calendar periods to which such records relate.

                  3.1   Royalty Reports Licensee will accompany each payment of
                        ---------------
                  running royalties with a report showing how the accompanying
                  payment was calculated and (if applicable) the rates at which
                  any foreign currencies were converted into U.S. dollars.

                  3.2   Audits Licensee will permit Licensor to audit Licensee's
                        ------
                  accounting records to verify the correctness of the
                  computations of running royalties due to Licensor hereunder.
                  Licensor will conduct any such audits at its own expense, at
                  reasonable times, and on reasonable advance notice to
                  Licensee.

                  3.2.1 Underpayments If an audit reveals that any payment of
                        -------------
                  running royalties has been understated by 2% or more, Licensee
                  will pay Licensor's expenses for that audit.

                  3.2.2 Audit Frequency Licensor may not audit Licensee more
                  than once each calendar year, unless an audit reveals an
                  underpayment of running royalties by 5% or more. In this
                  event, Licensor may, at Licensee's expense, audit Licensee as
                  frequently as once per calendar quarter, during the year
                  immediately subsequent to the 5% or more understatement.

         4.       Indemnification and Insurance Licensee will defend Licensor,
                  -----------------------------
         and will indemnify Licensor, and will hold Licensor harmless from, any
         claim that arises out of any act or activity licensed hereunder. This
         obligation of defense, indemnification and holding harmless includes
         the obligation to indemnify Licensor for its costs and attorneys fees
         in defending against any such claim.

                  4.1   Insurance Licensee agrees to maintain, during the term
                        ---------
                  of this agreement, general liability insurance policies
                  (including products, contractual and clinical testing
                  liability insurance) to cover all claims that arise out of any
                  act or activity licensed hereunder. Licensee agrees that such
                  policies will name Licensor as an insured. Licensee agrees to
                  place such policies with reputable and financially secure
                  insurance carriers.

                  4.1.1 Type of Policy Licensee agrees that the insurance
                        --------------
                  policies will afford primary coverage and will cover all
                  claims arising out of any act or activity licensed hereunder,
                  without regard to the date upon which such claim is discovered
                  or asserted.

                  4.1.2 Policy Limits Licensee agrees that the policy limits of
                        -------------
                  the insurance policies will be at least $1,000,000 per
                  occurrence, with a deductable of no more that $50,000.

                                        5

<PAGE>

                  4.1.3 Change of Policies or Insurance Carrier Licensee agrees
                        ---------------------------------------
                  not to change insurance carriers or forms of insurance
                  policies without reasonable advance notice to Licensor and
                  without Licensor's consent. Licensor may not unreasonably
                  withhold such consent.

                  4.1.4 Exception Licensee is not required to maintain insurance
                        ---------
                  coverage during the Investigative Phase defined in paragraph
                  2.3.1.

                  4.2   Notice Licensor will, as soon as practicable, notify
                        ------
                  Licensee of the assertion of any claim against Licensor that
                  Licensor considers to be covered by the provisions of
                  paragraph 4.

                  4.3   Survival After Termination The parties agree that
                        --------------------------
                  Licensee's obligation of defense, indemnification and holding
                  harmless defined in paragraph 4 above will continue
                  notwithstanding any termination of this agreement.

         5.       Termination The parties agree that Licensor, in its sole
                  -----------
discretion, may (but need not) terminate this agreement under any of the
circumstances enumerated in paragraph 5.1 below.

                  5.1   Circumstances  Licensor will have the right to terminate
                        -------------
this agreement if:

                        a)      Licensee breaches any material term hereof and
                                does not cure such breach within 60 days after
                                being given written notice that the breach
                                exists.

                        b)      Licensee files a petition in bankruptcy or is
                                adjudged a bankrupt.

                        c)      Licensee makes a general assignment for the
                                benefit of creditors or a receiver is appointed
                                for the business of Licensee and is not
                                discharged within 60 days after appointment.

                  5.2   Right of Termination is Cumulative The parties agree
                        ----------------------------------
                  that Licensor' right to terminate this agreement is cumulative
                  and in addition to all other legal rights and remedies that
                  Licensor may have against Licensee.

                  5.3   Termination Not Required to Bring Legal Action The
                        ----------------------------------------------
                  parties agree that Licensor need not terminate this agreement
                  as a condition precedent to bringing any legal action
                  (including arbitration) against Licensee.

                                        6

<PAGE>

                  5.4   Obligations Incurred Before Termination The termination
                        ---------------------------------------
                  of this agreement will not relieve Licensee of the obligation
                  to pay those financial obligations to Licensor that were
                  incurred before the date of termination.

                  5.5   Forbearance Licensor's exercise of forbearance, or
                        -----------
                  Licensor's delay in exercising any right to terminate this
                  agreement, will not prejudice Licensor's right to exercise any
                  legal right it may have against Licensee, including any right
                  it may have to terminate this agreement.

         6.       Marking Licensee agrees to mark all blood test results with
                  the following

35 U.S.C 8287 legend:

         Produced under a patent license to U.S. Patent No. 4,933,844.

         This paragraph 6 is a material term of this agreement.

         7.       Arbitration The parties agree to arbitrate any claim or
                  -----------
controversy arising out of or relating to this agreement or the breach thereof.
The parties agree that such arbitration will be conducted in New York County,
City of New York and State of New York in accordance with the rules then
obtaining of the American Arbitration Association. The parties agree that the
results of the arbitration will be binding upon them, and that judgement on the
arbital award may be entered in any court having jurisdiction thereof.

                  7.1   Exception The parties agree that in any arbitration of
                        ---------
                  this agreement, the arbitrator may not hold any of the Patent
                  Rights invalid, and may not invalidate any claim therein.

                  7.2   No Incidental, Consequential, or Punitive Damages The
                        -------------------------------------------------
                  parties agree that in any arbitration of this agreement, the
                  arbitrator may not award incidental, consequential, or
                  punitive damages.

                  7.3   New Jersey Law The parties agree that in any arbitration
                        --------------
                  of this agreement, the arbitrator will apply the substantive
                  law of the State of New Jersey.

         8.       Assignability  This agreement is personal to Licensee and may
                  -------------
not be assigned to any third party without Licensor's written consent. The
parties agree that any such assignment is void.

                  8.1   Licensor May Assign  Licensor may assign the Patent
                        -------------------
                        Rights without consent of Licensee.

                  8.2   Representatives, Successors, Etc.  This agreement, if
                        ---------------------------------
                        lawfully assigned, binds the parties' assigns,
                        successors, and transferees. The parties agree that this
                        agreement also binds the parties' legal representatives.

                                        7

<PAGE>

         9.       Miscellaneous Provisions  The following provisions apply to
                  ------------------------
this agreement:

                  9.1   Invalidity or Unenforceability If any provision of this
                        ------------------------------
                        agreement is invalid or unenforceable, or becomes
                        invalid or unenforceable under particular factual
                        circumstances, such invalidity or unenforceability will
                        not affect the validity or enforceability of any other
                        provision of this agreement.

                  9.2   Merger This agreement is the entire agreement between
                        ------
                        the parties, and supercedes any and all prior or
                        contemporaneous agreements relating to the same subject
                        matter.

                  9.3   Amendments to be in Writing  This agreement may not be
                        ---------------------------
                        amended except in a writing signed by the parties.

                  9.4   No Partnership, Agency etc.  This agreement does not
                        ---------------------------
                        create a partnership, an agency, or a joint venture
                        between the parties.

                  9.5   Notices The parties agree that all notices required or
                        -------
                        permitted under this agreement will be sent to the
                        parties' above-stated addresses, with copies as follows:

                  To Licensor                    To Licensee

                  Mark H. Jay, Esq               Fred D. Hutchison, Esq.
                  Siemens Corporation            Hutchison & Mason, PLLC
                  186 Wood Avenue South          4011 West Chase Boulevard
                  Iselin NJ 08830                Suite 400
                                                 Raleigh, NC 27607

                  9.6   No Warranties Licensee acknowledges Licensor does not
                        -------------
                  extend any warranties of any kind, whether express or implied,
                  regarding the Patent Rights. Without in any way limiting the
                  full generality of the foregoing sentence, Licensor hereby
                  disclaims any and all warranties of merchantability, and
                  fitness for intended purpose.

                  9.7   Confidentiality  The parties agree to keep the terms of
                        ----------------
                  this agreement confidential.

                                        8

<PAGE>

         10.      Effective Date  The Effective Date of this agreement is June
                  --------------
15, 1997.

                                            Siemens Medical Systems, Inc.

Date:  July 10, 1997                        By /s/ Wolfgang Kroll
                                               --------------------------------
                                            Wolfgang Kroll, its
                                            Executive Vice-President
                                            Duly Authorized

                                            LipoMed, Inc.

Date:                                       By /s/ Michael A. Harpold
                                               --------------------------------
                                            Michael A. Harpold, its President
                                            Duly Authorized

                                        9

<PAGE>

                       Exclusive License Agreement Between
                          Siemens Medical Systems, Inc.
                                       and
                                  LipoMed, Inc.

                                   Schedule A
                                   ----------

Canada Patent No. 1,327,933

Japan Patent Application No. 01-246216

Belgium Patent No. 0 361 214

Switzerland Patent No. 0 361 214

Germany Patent No. 68916729.6

Spain Patent No. 0 361 214

France Patent No. 0 361 214

Great Britain Patent No. 0 361 214

Italy Patent No. 0 361 214

Netherlands Patent No. 0 361 214

                                       10<PAGE>

                                                                    Exhibit 10.6

   Confidential Materials omitted and filed separately with the Securities and
                Exchange Commission. Asterisks denote omissions.

                             COLLABORATION AGREEMENT
                                     BETWEEN
                     LIPOMED INC. OF RALEIGH, NC ("LIPOMED")
                                       AND
              BRUKER INSTRUMENTS, INC. OF BILLERICA, MA ("BRUKER")

LipoMed and Bruker wish to collaborate on the adaptation, further development
and deployment of Bruker's INCA(TM) (Integrated NMR Clinical Analyzer) for
LipoMed's NMR LipoProfile(R) clinical laboratory test for blood lipoprotein
levels.

As part of this Collaboration Agreement ("Agreement"), Bruker and LipoMed agree
as follows:

1.   A previously executed Confidential Disclosure Agreement, dated September
     14, 1998, shall be extended for the duration of the Agreement.

2.   LipoMed, including any subsidiaries or licensees of LipoMed, shall commit
     to the purchase of at least [**] INCA 400 MHz systems within 36 months of
     the execution date of the Agreement. The systems will include Phase 1
     technology, described below, and will optionally be equipped with Phase 2
     technology should LipoMed so decide. Timing of the ordering and delivery of
     individual INCA units will be linked to development milestones as specified
     in Appendix A such that any delay in meeting or failure to meet such
     milestones shall correspondingly extend the 36 months for purchase of the
     requisite INCA systems.

3.   Bruker shall be responsible for the adaptation and further development of
     its present INCA system to meet LipoMed's specifications. Bruker will not
     charge LipoMed any development costs associated with these adaptations and
     further developments, unless specifically stated below. LipoMed will assist
     Bruker with the design and testing of the Phase 1 and Phase 2 technologies.
     However, Bruker retains all commercial and patent rights (if any) for these
     developments subject to any commercial and patent rights held or applied
     for by LipoMed with respect to its NMR LipoProfile technology or otherwise
     directly related to LipoMed's proprietary methods or technologies.

4.   LipoMed and Bruker shall establish a Joint Development Team to formulate
     specifics of the development plan, including, but not limited to, project
     goals, specifications, milestones and testing. This Joint Development Team
     will consist of Drs. James Otvos and David Morgan (LipoMed), Werner Maas
     (Bruker Project Manager for INCA), and Tonio Gianotti (Bruker NMR Head of
     R&D). As needed, other individuals may be added to address specific project
     planning and execution issues.

<PAGE>

5.   LipoMed is aware that the INCA is not cleared by the U.S. FDA. LipoMed
     accepts all responsibility and costs associated with obtaining FDA (or an
     equivalent international organization's) clearance or adherence to its
     regulations. Bruker will make available any documentation needed to pursue
     this matter. It will be Bruker's responsibility to ensure that its
     equipment adheres to common international safety and quality standards as
     they relate to scientific equipment (Bruker is ISO 9001 certified and it's
     equipment meets CE standards. Bruker will promptly notify LipoMed if
     Bruker's ISO status changes or if its equipment fails to meet such CE
     standards).

6.   The INCA system is a fully functional NMR system and consists of the
     following subunits:

   .   INCA protective enclosure containing all subunits.
   .   New UltraShield II(TM) 400 MHz 54 mm magnet with lifting mechanism for
       service
   .   New, space-saving AVANCE 400 console [**].
   .   Shims, preamplifiers, [**] probe with automatic tuning capability.
   .   Pentium PC computer (complete) with NT operating system, [**], flat panel
       external LCD Touchscreen monitor and a Touchscreen NMR Interface.
   .   Unit 1 will be delivered with the NMR Case(TM) sample changer with new
       PLC controls.

7.   Bruker shall develop in Phase 1:

   .   A high capacity (More than [**] samples) automated sample delivery system
       capable of generating NMR LipoProfile data on plasma samples Less than or
       equal to [**] ml at a rate of [**] sample/[**].
   .   A new sample container format suitable for high through-put operation
       (container material, dimensions, and cost to be finalized during
       Collaboration).
   .   A means of [**] samples to the [**] prior to [**] the [**] for analysis.
   .   A modified [**] NMR probe with [**] and [**] suitable for non-spinning
       new-format samples.
   .   A modified INCA-GUI for executing automated NMR LipoProfile blood plasma
       testing, tailored for use by clinical laboratory technicians. The
       detailed specifications for this GUI will be defined by the Joint
       Development Team, with detailed input from LipoMed. Note: If LipoMed
       requires GUI software capabilities beyond those specified in advance by
       the Joint Development Team, it may develop these in-house at its own
       expense. Bruker will assist in this effort by making available to LipoMed
       on a confidential basis whatever documentation and source code is needed.
       Alternatively, LipoMed can contract with Bruker for additional software
       development services at a discounted professional services rate of $1,000
       per day, or $150 per hour, not including travel and additional expenses.

       Bruker and LipoMed agree that during the Phase 1 development effort the
       present technical concepts could be modified substantially in order to
       achieve the sample throughput, data quality and reliability required for
       LipoMed's use of INCA. Since Bruker is not equipped to handle hazardous
       biological materials (ie., blood plasma), all plasma testing will be
       conducted at LipoMed on a prototype INCA system. Testing at Bruker shall
       be restricted to suitable non-hazardous samples to be supplied by
       LipoMed. Once Phase 1 is successfully completed, development of Phase 2
       will begin.

                                        2

<PAGE>

8.   In the optional Phase 2, Bruker shall develop the following adaptations:

    .  A mechanism of transporting samples, or sample racks, to the rapid sample
       changer to enable unattended analysis of at least 300 samples, either by
       means of a new automated sample tray changer (ASTC) or any other method
       deemed suitable by the Joint Development Team.
    .  A modified GUI for executing automated NMR LipoProfile blood plasma
       testing on batches of at least 300 samples, tailored for use by clinical
       laboratory technicians. The detailed specifications for this GUI will be
       defined by the Joint Development Team, with detailed input from LipoMed.
       Note: If LipoMed requires GUI software capabilities beyond those
       specified in advance by the Joint Development Team, it may develop these
       in-house at its own expense. Bruker will assist in this effort by making
       available to LipoMed on a confidential basis whatever documentation and
       source code is needed. Alternatively, LipoMed can contract with Bruker
       for additional software development services at a discounted professional
       services rate of $1,000 per day, or $150 per hour, not including travel
       and additional expenses.

       Phase 2 will begin after Phase 1 is finished, and will take approximately
       twelve months.

9.   It is agreed that sample collection, storage, preparation, and transfer to
     the NMR measurement container, sample (or sample tray) labeling for
     unambiguous identification, sample positioning in the NMR sample tray,
     sample disposal after measurement, and commercial aspects of testing (e.g.
     patient info, billing, etc.), as well as all consumables are the sole
     responsibility of LipoMed, and are not included in the Collaboration
     Agreement.

10.  The price for each of the first [**] INCA systems sold to LipoMed,
     including items developed or adapted in Phase 1, plus installation,
     training, and a one-year warranty is $[**]. Accessory items developed or
     adapted in Phase 2 are priced at $[**] for each INCA system, including
     installation and a one-year warranty. Payment terms for the first [**]
     systems are outlined in Appendix A.

11.  The price for additional INCA systems (which include Phase 1 accessories)
     beyond the first [**] sold to LipoMed shall be negotiated, but will not
     exceed $[**] each. The price for the Phase 2 accessories shall not exceed
     $[**].

12.  In consideration for LipoMed's commitment to purchase [**] INCA systems in
     accordance with paragraph 2 of this Agreement, Bruker will not knowingly
     sell or utilize its INCA systems (or Phase 1 or Phase 2 accessories) for
     commercial use in lipoprotein and subclass analysis in the fields of
     cardiovascular disease and diabetes (the "Restricted Field") during such
     initial 36-month period. Bruker further agrees that for a period of seven
     years following such initial three-year period, it will not knowingly sell
     or utilize its INCA system for commercial use in the Restricted Field
     provided that LipoMed, including its subsidiaries, affiliates or licenses,
     purchases at least [**] additional INCA systems each year.

13.  The parties agree that upon development of the sample containers to be used
     with the rapid sample changer and agreement on the container
     specifications, they will negotiate in good

                                        3

<PAGE>

       faith a supplier agreement between LipoMed and Bruker for such sample
       containers. Provided, however, that LipoMed agrees not to reverse
       engineer Bruker proprietary sample formats which Bruker NMR develops for
       the INCA or other high-throughput NMR systems.

14.    INSTALLATION, WARRANTY AND SERVICE
       Bruker NMR remains responsible for installation, warranty service and
       post-warranty service of all INCA systems. The purchase of each INCA
       system includes one installation and demonstration of specifications by
       Bruker NMR free-of-charge. The cost of customer site preparation
       according to Bruker's site planning guide, or rigging and transportation
       of the system into the LipoMed or customer lab, and consumables required
       for the installation are not included in the Bruker NMR OEM price.
       Additional installations, if any, will be billed by Bruker NMR to LipoMed
       at normal posted service rates. Each system price includes a one-year
       limited warranty under Bruker's standard warranty terms. The period of
       warranty is one year following demonstration of specifications, but in
       any event not more than 15 months after delivery. Warranty covers both
       parts and labor. For those items supplied but not manufactured by Bruker,
       the warranty terms of the manufacturer will be transferred to the buyer.
       After the expiration of the one-year limited warranty LipoMed, or the
       final customer, may purchase additional annual Maintenance Service
       Agreements (MSA) or per-call service from the Bruker service organization
       in each country at normal MSA or per-call service rates, posted in each
       country from time to time. If a customer requires additional response
       time guarantees, or 24/7 coverage, then Bruker's standard surcharges to
       the normal MSA rates will apply.

       LipoMed will remain responsible for service issues not related to the
       automated NMR data acquisition, such as sample preparation and handling,
       administration, patient billing and data tracking.

15. GENERAL TERMS AND CONDITIONS

 15.1.   LipoMed and Bruker will jointly and by mutual agreement develop and
         release a press release and other related statements, explaining the
         benefits of this Agreement to future customers.

 15.2.   Neither party acquires any intellectual property rights under this
         Agreement except the limited rights necessary to carry out the purposes
         set forth in paragraph 12.

 15.3.   Both parties shall adhere to all applicable laws, regulations and rules
         relating to the export of technical data and equipment. LipoMed shall
         not export or re-export any Bruker product or technical data to any
         proscribed country listed in such applicable laws, regulations and
         rules unless properly authorized. Bruker shall be solely responsible
         for compliance with all applicable laws, regulations and rules relating
         to the import of equipment, parts or technology for the INCA systems.

 15.4    This Agreement does not create any agency or partnership relationship.

                                        4

<PAGE>

 15.5.   All additions or modifications to this Agreement must be made in
         writing and must be signed by both parties.

 15.6.   Drafts to this agreement were exchanged and drafted by both parties
         hereto, and accordingly this Agreement shall be considered jointly
         drafted.

 15.7    This Agreement is made under, and shall be construed according to, the
         laws of the Commonwealth of Massachusetts.

For LipoMed:                                 For Bruker:

/s/ Richard A. Franco                        /s/ Frank H. Laukien
-----------------------------------          -----------------------------------

Richard A. Franco                            Frank H. Laukien, Ph.D.
CEO, Lipomed, Inc.                           President, Bruker Instruments, Inc.

Date: 3/2/00

                                        5

<PAGE>

                                   APPENDIX A

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------

Approximate          Development                   Order/Delivery                  Payment
   Date               Milestones                      Schedule                     Schedule

-----------------------------------------------------------------------------------------------
<S>              <C>                               <C>                           <C>
[**]               Commence Phase 1 planning            [**]                      $[**] ([**]%)

                       Make [**] decision

                       Make [**] decision

[**]                                                  [**] and [**] at LM         $[**] ([**]%)

                    Determine [**] via plasma
                            [**] at LM

                   Demonstrate Phase 1 [**] at
                             Bruker

                     Develop and test [**]
[**]                                                   [**] Phase 1 [**]          $[**] ([**]%)

                    [**] Phase 1 [**] at LM

                      [**] software at LM

[**]                                               [**] Phase 1 [**] and [**]     $[**] ([**]%)

[**]               Begin Phase 2 development                  [**]                $[**] ([**]%)

[**]                                               [**] and [**] [**] with        $[**] ([**]%)
                                                         Phase 1 [**]
-----------------------------------------------------------------------------------------------

Approximate          Development                   Order/Delivery                  Payment
   Date               Milestones                      Schedule                     Schedule

-----------------------------------------------------------------------------------------------
[**]                                                            [**]              $[**] ([**]%)
[**]                                              [**]                            $[**] ([**]%)
                   Demonstrate Phase 2 [**] at
                             Bruker

                                                    [**] Phase 2 [**] for [**]    $[**]([**]%)

[**]                                                [**] and [**] [**] with       $[**]([**]%)
                                                         Phase 1  [**]
</TABLE>

                                        6

<PAGE>

[**]                   [**]                                $[**]([**]%)
[**]                       [**] Phase 2 [**] on [**]       $[**]([**]%)[**]

[**]                      [**] of Phase 2 [**] on [**]     $[**]([**]%)

[**]                       [**] with Phase 1 & 2 [**]      $[**]([**]%)

[**]                             [**] and [**]             $[**]([**]%)

[**]                   [**]                                $[**]([**]%)
[**]                       [**] with Phase 1 & 2 [**]      $[**]([**]%)

[**]                   [**] and [**]                       $[**]([**]%)

[**]                   [**] of [**]                        $[**]([**]%)

--------------------------------------------------------------------------------

                                        7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00041-of-00352.parquet"}]]